Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression by Eisele, Günter et al.
CLINICAL STUDY
Cilengitide treatment of newly diagnosed glioblastoma
patients does not alter patterns of progression
Gu¨nter Eisele • Antje Wick • Anna-Carina Eisele • Paul M. Cle´ment •
Jo¨rg Tonn • Ghazaleh Tabatabai • Adrian Ochsenbein • Uwe Schlegel •
Bart Neyns • Dietmar Krex • Matthias Simon • Guido Nikkhah •
Martin Picard • Roger Stupp • Wolfgang Wick • Michael Weller
Received: 16 October 2013 / Accepted: 8 January 2014 / Published online: 19 January 2014
 Springer Science+Business Media New York 2014
Abstract The integrin antagonist cilengitide has been
explored as an adjunct with anti-angiogenic properties to
standard of care temozolomide chemoradiotherapy (TMZ/
RT ? TMZ) in newly diagnosed glioblastoma. Preclinical
data as well as anecdotal clinical observations indicate that
anti-angiogenic treatment may result in altered patterns of
tumor progression. Using a standardized approach, we ana-
lyzed patterns of progression on MRI in 21 patients enrolled
onto a phase 2 trial of cilengitide added to TMZ/RT ? TMZ
in newly diagnosed glioblastoma. Thirty patients from the
experimental treatment arm of the EORTC/NCIC pivotal
TMZ trial served as a reference. MRIcro software was used
to map location and extent of initial preoperative and
recurrent tumors on MRI of both groups into the same ste-
reotaxic space which were then analyzed using an automated
tool of image analysis. Clinical and outcome data of the
cilengitide-treated patients were similar to those of the EO-
RTC/NCIC trial except for a higher proportion of patients
with a methylated O6-methylguanyl-DNA-methyltransfer-
ase gene promoter. Analysis of recurrence pattern revealed
neither a difference in the size of the recurrent tumor nor in
the distance of the recurrences from the preoperative tumor
location between groups. Overall frequencies of distant
recurrences were 20 % in the reference group and 19 % (4/
21 patients) in the cilengitide group. Compared with TMZ/
RT ? TMZ alone, the addition of cilengitide does not alter
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concerns that integrin antagonism by cilengitide may induce
a more aggressive phenotype at progression, but also pro-
vides no evidence for an anti-invasive activity of cilengitide
in patients with newly diagnosed glioblastoma.
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Introduction
Most current efforts to improve the outcome for patients with
newly diagnosed glioblastoma focus on the addition of anti-
angiogenic agents to the standard of care of concomitant
chemoradiotherapy with temozolomide (TMZ/RT ? TMZ)
[1]. The majority of pharmacological approaches focus on
inhibition of the vascular endothelial growth factor (VEGF)
pathway, but additional targets are being explored, notably
integrins. Preclinical data obtained in rodent glioma models
suggest that VEGF antagonism may induce a more infiltra-
tive, disseminated phenotype of gliomas [2, 3]. No such
animal data are available for integrin antagonism.
We have previously developed an analysis tool to
explore whether comparable groups of patients differ in
their patterns of progression. This tool was first used for
analysis of the pivotal EORTC/NCIC TMZ trial; and
allowed to falsify the hypothesis that the addition of TMZ
to RT alters the pattern of progression of glioblastomas [4].
Similarly, using this tool we did not confirm the notion that
bevacizumab therapy alters tumor biology to a more
invasive phenotype [5]. In the present study, we asked
whether patients treated with the integrin antagonist cil-
engitide would exhibit an altered pattern of progression.
Patients and methods
We retrieved the matched pre- and post-operative MRI
scans as well as the MRI scan documenting progression of
patients enrolled into a single-arm phase 2 clinical trial of
cilengitide plus TMZ/RT ? TMZ in newly diagnosed
glioblastoma [6]. Thirty patients from the experimental
treatment arm of the EORTC/NCIC 26981/22981 National
Cancer Institute of Canada (NCIC) CE.3 trial served as a
references [1, 4]. From these patients MRI scans at baseline
and progression were available for a retrospective recur-
rence pattern analysis [4]. Patterns of progression were
analyzed as described [4]; in brief, brain lesions were
demonstrated by contrast-enhanced T1-weighted MRI
sequences. The MR scans were oriented along the bicom-
missural plane. Mapping of lesions was performed blinded
to the clinical features of the patients. The boundaries of
the tumor location at baseline and at follow-up were
delineated using MRIcro software [7] and mapped on the
T1-template MRI from the Montreal Neurological Institute
(www.bic.mni.mcgill.ca/cgi/icbm_view) that is distributed
with MRIcro. Tumors were mapped for each individual
patient, with separate tumor maps generated for both the
baseline and recurrence scan. By transforming each indi-
vidual brain and lesion into the same stereotaxic space, the
procedure allowed us to superimpose lesions of different
individuals to find regions of mutual involvement and
conduct subtraction analysis. These techniques are well
established in stroke research and have been applied to
brain tumor patients before [4, 5].
Further, by using MRIcro, tumor volume and the loca-
tion of the center-of-mass of the tumor for each individual
were computed. The center-of-mass is the mean position
for all tumor-affected voxels in each of the three spatial
dimensions, resulting in a single cartesian coordinate
(X, Y, Z position). In the case of a single spherical tumor,
the center-of-mass thus will be located right in its center,
while with, e.g. a U-shaped configuration the center-of-
mass may lie outside the tumor itself. Likewise this mea-
sure is influenced by satellites of the main tumor mass and
thus sensitive to the development of satellites between
baseline and recurrent images.
For an additional case-by-case analysis a distant recur-
rence on T1 contrast-enhanced (T1?c) sequences was
defined as one of the following: (a) qualitative assessment
of well-defined recurrence centered outside a 2 cm margin
around the outer border of the primary site or margin of the
resection cavity or a shift of the center-of-mass by more
than half of the diameter of the pretreatment tumor, (b) new
tumor satellites, (c) new involvement of the contralateral
hemisphere [4]. Only patients with progressive disease
(PD) as the reason for failure of therapy were included.
Analysis was done blinded to treatment in the reference or
cilengitide group on contrast-enhanced T1-weighted ima-
ges in the axial plane. The boundary of the tumor location
at baseline and at follow-up was delineated using OsiriX
software (Softonic, Stanford, CA, USA).
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A two-tailed t test was conducted to determine if the two
treatments influenced the size of recurrent tumors or the
distance of the center-of-mass between the baseline and
follow-up scan or both. A sample size of 20 per group
would be sufficient to detect a 35 % difference for the
movement of the center-of-mass with a power of 70 % that
would be regarded clinically relevant.
Median progression-free and overall survival for the
cilengitide group were calculated by Kaplan–Meier sur-
vival analysis using SPSS software version 21 for Win-
dows (IBM, Armonk, NY, USA).
Results
For 21 representative patients (21/53, 40 %) treated pro-
spectively within the cilengitide added to standard TMZ/
RT ? TMZ 010 pilot phase II protocol complete digitized
imaging was available for review and analysis [6]. The
reference group included all 30 patients with sufficient
MRI information from the experimental arm of the EORTC
26981/22981 NCIC CE.3 trial, as previously reported [1,
4]. Table 1 summarizes characteristics of the patients,
tumors and outcome of the two cohorts. Overall, patient
characteristics appear comparable, with the exception of a
higher proportion of patients with an unknown
O6-methylguanyl-DNA-methyltransferase (MGMT) meth-
ylation status in the historical reference cohort (23 vs 14 %).
Patients in both groups did not differ with respect to extent
of resection. The median time between imaging used for the
baseline MRI scanning and first histological diagnosis was
0.2 months in both groups. The median time between
baseline MRI and the MRI demonstrating recurrence was
7.3 months in the reference group and 9.0 months in the
cilengitide group, comparable to the whole study cohort.
To identify any preferential directions of tumor growth
or of tumor shrinkage in either group, the tumor locations
at baseline were subtracted from the superimposed tumor
locations after treatment in each treatment group. For both
treatment groups, we found no marked anatomical shift of
tumor locations after treatment. The overlap frequencies
after substraction did not exceed 35 % of overlap at any
Table 1 Patient characteristics
Patient characteristics MRI study cohort from [6]
(n = 21)
Complete study cohort from
[6] (n = 52)
Reference cohort from EORTC
26981-22981 NCIC CE3 [1, 4] (n = 30)
No. of patients % No. of patients % No. of patients %
Age, years
Median 53 57 56
Range 32–67 32–68 36–66
Sex
Male 11 52 32 62 18 60
Female 10 48 20 38 12 40
ECOG performance status KPSa
0 or 1 20 95 48 92 90–100: n = 18 60
2 1 5 4 8 70–80: n = 12 40
Prior treatment
Corticosteroids 19 90 43 83 23 77
Debulking surgery 18 86 43 83 18 60
Complete resection 9 43 23 44 n/a
Partial resection 9 43 20 39 n/a
Biopsy 3 14 9 17 12
MGMT promoter status
Methylated 9 43 23 44 10 33
Unmethylated 9 43 22 42 13 43
Unknown 3 14 7 13 7 23
Median PFS (months, 95 % CI) 8.1 (6.4–9.8) 8.0 (6.0–10.7) 7.1 (5.8–8.2)
Median OS (months, 95 % CI) 15.7 (11.2–20.1)b 16.1 (13.1–23.2) 14.4 (13.4–16.8)
a Eastern cooperative oncology group (ECOG) measure 0 = KPS 100; ECOG 1 = KPS 80–90; ECOG 2 = KPS 60–70, according to [13]. KPS
Karnofsky performance status, CI confidence interval, n/a information not available, PFS progression-free survival, OS overall survival
b 5 Patients censored
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location indicating that the anatomical differences between
baseline and follow-up measurement were small and not
directionally specific.
Recurrent tumor volumes (measured in voxels on a per-
patient basis) were 1.29-fold (±0.37) and 1.4-fold (±0.41)
larger than the initial tumors in the reference group and in
the cilengitide group, respectively (p = 0.51)
For the center-of-mass measure, the distance between
baseline and follow-up centroids was computed for each
individual, providing a measure of excentricity or a large shift
in location, e.g., when a new satellite tumor has developed.
The movement of the center-of-mass between the baseline
and follow-up scan in the reference cohort and the cilengitide
cohort revealed no difference with a mean movement of
12.03 mm (±0.39) for the reference group and 13.22 mm
(±0.60) for the cilengitide treated patients (p = 0.53). The
case-by-case comparison suggested the same conclusion: the
frequency of distant recurrences was 18 % in the reference
and 19 % in the cilengitide group (v2 = 0.92, p = 0.12).
Discussion
The patterns of progression in glioblastoma have recently
attracted a lot of interest, both because of preclinical data
and clinical observations that suggested a specific change
in the pattern of progression depending on treatment, i.e.
radiotherapy, TMZ chemotherapy or novel anti-angiogenic
treatments [2, 3, 8–10]. Using a previously established and
standardized tool and radiological software we compared
the pattern of progression of 21 patients who were pro-
spectively treated with cilengitide in addition to standard
TMZ/RT ? TMZ with 30 reference patients who received
standard chemoradiotherapy alone in a previous clinical
trial. In contrast to the initial hypothesis, we did not
demonstrate a difference in invasion pattern or location of
tumor recurrence (e.g. farther distance from the initial
tumor location) for the patients having been treated with
cilengitide. Interestingly, one patient from the cilengitide
group who experienced a local recurrence intracranially
was diagnosed with histologically proven pulmonary
metastasis in the course of the disease. However, this case
is exceptional and no further patients with systemic
metastasis were described in this trial [6].
Similar to cilengitide and despite strong preclinical
evidence of development of a more aggressive phenotype
and increased invasion after treatment with bevacizumab
[2, 3, 10], a recent analysis of the imaging data of patients
treated in the AVAGlio trial (bevacizumab added to TMZ/
RT ? TMZ) did not indicate a clinically relevant change
in invasion pattern or tumor phenotype in bevacizumab-
treated patients [11]. Yet, it is noteworthy that RTOG-
0825, a similar trial, reported impaired quality of life and
decreased scores on some tests of cognitive function in
bevacizumab-treated patients, although no such data were
reported by the AVAGlio investigators [11, 12]. Careful
comparison of both data sets including neuroimaging will
be necessary to better understand these conflicting data and
a possible role of neuroimaging changes.
While preclinical evidence suggested anti-invasive
properties of TMZ, or potentially promotion of invasive
escape mechanisms after irradiation, or after VEGF inhi-
bition, systematic analyses of the pattern of treatment
failure does not substantiate these findings in the clinical
setting. Although all analyses were conducted on relatively
small subsets of patients, the consistency of the finding
raises questions to whether the preclinical models reflect
the human situation adequately.
This is the first analysis ever of a potential modulation
of patterns of progression by the novel class of compounds
of integrin inhibitors. The observation that no change in the
patterns of progression in a cohort of cilengitide-treated
patients compared to a cohort of patients from the experi-
mental arm of the EORTC 26981/22981 NCIC CE.3 was
observed is reassuring. The major limitation of the present
study is the small sample size and the uncertainty of its
relevance in the future: preliminary results from the sub-
sequently performed phase 3 trial, CENTRIC, indicate that
the primary endpoint of prolonging overall survival was
not reached [13]. Yet, our analysis serves as a baseline and
reference for the future study of the role of modulation of
integrins in the treatment of newly diagnosed glioblastoma.
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